Want to learn more about Lunit AI Solutions? Let’s connect! Contact Us

A universal immunohistochemistry analyzer for generalizing AI-driven assessment of immunohistochemistry across immunostains and cancer types

Biagio Brattoli et al. - NPJ Precision Oncology 2024

AUTHORS

Biagio Brattoli, Mohammad Mostafavi, Taebum Lee, Wonkyung Jung, Jeongun Ryu, Seonwook Park, Jongchan Park, Sergio Pereira, Seunghwan Shin, Sangjoon Choi, Hyojin Kim, Donggeun Yoo, Siraj M. Ali, Kyunghyun Paeng, Chan-Young Ock, Soo Ick Cho & Seokhwi Kim

1Lunit, Seoul, Republic of Korea. 2Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine,

Seoul, Republic of Korea. 3Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. 4Department of Pathology, Ajou

University School of Medicine, Suwon, Republic of Korea. 5Department of Biomedical Sciences, Ajou University

Graduate School of Medicine, Suwon, Republic of Korea. 6These authors contributed equally: Biagio Brattoli,

Mohammad Mostafavi, Taebum Lee.

PUBLISHED

NPJ Precision Oncology 2024

Immunohistochemistry (IHC) is the common companion diagnostics in targeted therapies. However, quantifying protein expressions in IHC images present a significant challenge, due to variability in manual scoring and inherent subjective interpretation. Deep learning (DL) offers a promising approach to address these issues, though current models require extensive training for each cancer and IHC type, limiting the practical application. We developed a Universal IHC (UIHC) analyzer, a DL-based tool that quantifies protein expression across different cancers and IHC types. This multi-cohort trained model outperformed conventional single-cohort models in analyzing unseen IHC images (Kappa score 0.578 vs. up to 0.509) and demonstrated consistent performance across varying positive staining cutoff values. In a discovery application, the UIHC model assigned higher tumor proportion scores to MET amplification cases, but not MET exon 14 splicing or other non-small cell lung cancer cases. This UIHC model represents a novel role for DL that further advances quantitative analysis of IHC.

Read the full paper
BiomarkerLunit SCOPEOncologyPathology

More from Blog

No Data